Bristol-Myers Squibb, Princeton, New Jersey, USA.
Bristol-Myers Squibb, Shanghai, China.
Clin Pharmacol Ther. 2019 Feb;105(2):363-375. doi: 10.1002/cpt.1017. Epub 2018 Mar 8.
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.
在中国，癌症是一个日益严重的公共卫生问题。尽管中国癌症患者存在未满足的巨大医疗需求，但肿瘤药物的批准数量历来落后于西方，主要是美国和欧洲。为了缩小这一差距，中国目前正在快速推进监管改革。
